SVB Securities analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) on May 15. The company’s shares closed yesterday at $4.49.
According to TipRanks, Graybosch is an analyst with an average return of -18.5% and a 31.48% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as BioNTech SE, Merck & Company, and Nektar Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nkarta with a $24.67 average price target, implying a 449.44% upside from current levels. In a report released on May 12, Mizuho Securities also maintained a Buy rating on the stock with a $26.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $18.48 and a one-year low of $3.12. Currently, Nkarta has an average volume of 425.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nkarta Inc is a bio-pharmaceutical company focused on the discovery, development and commercialization of engineered, allogeneic, and off-the-shelf cell therapies to treat cancer.
Read More on NKTX:
- Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
- Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
- Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
- Nkarta to Participate at Upcoming Investor Conferences
- Nkarta chief financial and business officer resigns
